AstraZeneca PLC is primarily active in the pharmaceutical and biotechnology industries.

AstraZeneca PLC's main competitors in the market include pharmaceutical companies such as Pfizer, GlaxoSmithKline, and Novartis. These companies also operate in the healthcare sector and offer a wide range of prescription drugs, vaccines, and consumer health products. However, AstraZeneca PLC has carved a niche for itself with its innovative research and development initiatives, particularly in the field of oncology and respiratory diseases. Their commitment to addressing unmet medical needs differentiates them from competitors in the pharmaceutical industry.

AstraZeneca PLC is a renowned British-Swedish multinational pharmaceutical and biopharmaceutical company. Established in 1999 through a merger, AstraZeneca has a rich history dating back to the 19th century. The company specializes in innovative prescription medicines, biologics, and oncology therapies that improve the health and well-being of millions of people worldwide. AstraZeneca is dedicated to developing groundbreaking treatments for various therapeutic areas, including cardiovascular, respiratory, metabolic, and autoimmune diseases, as well as cancer. With a steadfast commitment to research and development, AstraZeneca continues to make significant contributions to the global healthcare industry, improving patients' lives and advancing medical science.

AstraZeneca PLC, a renowned pharmaceutical company, has achieved several significant milestones. Firstly, they have made remarkable advancements in the field of cancer treatment, particularly with drugs like Tagrisso and Lynparza, aiding patients worldwide. Secondly, AstraZeneca has developed lifesaving medications for chronic respiratory diseases, including Symbicort and Pulmicort, improving the quality of life for millions. Furthermore, AstraZeneca's COVID-19 vaccine, developed in collaboration with the University of Oxford, has played a pivotal role in combating the global pandemic. Their dedication to scientific innovation and commitment to global health has positioned AstraZeneca PLC as a prominent leader in the pharmaceutical industry.

AstraZeneca PLC is primarily present in multiple countries and regions across the globe. The company operates in the United States, United Kingdom, Sweden, France, Germany, China, Brazil, Canada, Japan, and many others. With a robust global footprint, AstraZeneca PLC's presence spans across North America, Europe, Asia-Pacific, Latin America, and the Middle East. As a renowned pharmaceutical company, AstraZeneca PLC delivers innovative medicines and healthcare solutions to enhance patient lives worldwide.

AstraZeneca PLC represents values of innovation, integrity, and patient-centricity in its corporate philosophy. As a leading global pharmaceutical company, AstraZeneca is dedicated to transforming the lives of patients through scientific advancements and breakthrough treatments. The company is committed to ethical business practices, ensuring transparency and accountability in all its operations. With a focus on collaboration and strategic partnerships, AstraZeneca aims to address unmet medical needs and improve healthcare worldwide. By combining cutting-edge research and a patient-first approach, AstraZeneca continues to pave the way for the development of innovative and life-saving medicines.

Analysts currently set an average price target of 20,977.47 USD for the AstraZeneca stock (median: 21,980.93 USD), implying +11,704.6 % versus the latest price. The consensus is based on 34 analyst ratings.

AstraZeneca Analyst Price Targets 2026

34 analysts currently rate the AstraZeneca stock: 28 recommend buying, 5 holding and 1 selling. For 2026, analysts expect AstraZeneca to generate revenue of 63.30 B USD and earnings per share of 10.25 USD.

AstraZeneca Analyst Price Targets 2026

Converted at the current exchange rate, the AstraZeneca share trades at 154.13 EUR (177.71 USD).

The AstraZeneca share (AZN.L) is listed on 11 stock exchanges, including: XETRA (ZEG.DE), Frankfurt (ZEG.F), München (ZEG.MU), Düsseldorf (ZEG.DU), Hamburg (ZEG.HM), London (AZN.L), London (AZN.L), SIX (Zürich) (AZN.SW).

AstraZeneca PLC is a globally operating pharmaceutical company focused on research, development, and distribution of innovative medications in the fields of cancer, cardiovascular, respiratory, immunology, and infectious diseases. It was founded in 1999 by the merger of Astra AB and Zeneca Group plc. The company is headquartered in London, UK, and employs over 70,000 employees in 100 countries worldwide. AstraZeneca consists of three main business segments: Innovative Medicines and Early Development (IMED), Global Product and Portfolio Strategy (GPPS), and BioPharmaceuticals. The company's focus is on developing and marketing innovative medications for treating a variety of diseases and conditions. IMED is AstraZeneca's key business segment and encompasses the research and development of new medications. This includes innovative active substances and therapies that have the potential to fundamentally improve disease treatment. Some current research focuses include cancer therapy, immunology, respiratory diseases, and cardiovascular diseases. GPPS is responsible for the marketing and portfolio management of AstraZeneca's pharmaceuticals. This includes strategic decision-making regarding which medications should continue to be developed and brought to market. GPPS also has responsibility for the distribution channels and pricing strategy of medications, ensuring both the company's profitability and the availability of medications for patients worldwide. BioPharmaceuticals is another important business segment of AstraZeneca, focusing on the production, distribution, and marketing of medications. This primarily includes biological therapies used for the treatment of cancer, inflammatory diseases, and autoimmune diseases. Some of AstraZeneca's most well-known medications include Nexium, a treatment for gastric ulcers and heartburn; Crestor, a cholesterol-lowering drug; and Symbicort, an inhaler for the treatment of asthma and chronic bronchitis. Additionally, AstraZeneca is actively involved in developing new medications, including promising cancer therapies such as Tagrisso, Lynparza, and Imfinzi. An essential part of AstraZeneca's business model is collaboration with other companies and institutions through partnerships and cooperation. Through targeted collaborations and acquisitions, the company expands its portfolio of medications and strengthens its position in the competition. Overall, AstraZeneca's business model is focused on developing, manufacturing, and marketing innovative and effective medications to achieve improvements in patient care and treatment, thereby contributing to the well-being of society. Output: AstraZeneca PLC is a globally operating pharmaceutical company focused on research, development, and distribution of innovative medications. It was founded in 1999 and is headquartered in London, UK. The company employs over 70,000 employees in 100 countries. AstraZeneca consists of three main business segments: Innovative Medicines and Early Development (IMED), Global Product and Portfolio Strategy (GPPS), and BioPharmaceuticals. IMED focuses on research and development of new medications, while GPPS handles marketing and portfolio management. BioPharmaceuticals focuses on production, distribution, and marketing. AstraZeneca is known for medications such as Nexium, Crestor, and Symbicort. The company collaborates with other companies and institutions through partnerships and cooperation. Overall, AstraZeneca aims to develop, manufacture, and market effective medications to improve patient care and contribute to society.

The expected revenue of AstraZeneca is 63.30 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of AstraZeneca is 16.01 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of AstraZeneca is currently 17.34. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the AstraZeneca stock.

The price-to-sales ratio (P/S) of AstraZeneca is currently 4.39. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the AstraZeneca stock.

The Eulerpool Quality Score for AstraZeneca is 8/10.

The ISIN of AstraZeneca is GB0009895292. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of AstraZeneca is 886455. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of AstraZeneca is AZN.L. The ticker symbol is used to trade AstraZeneca shares on the stock exchange.

Over the past 12 months, AstraZeneca paid a dividend of 4.54 USD . This corresponds to a dividend yield of about 2.55 %. For the coming 12 months, AstraZeneca is expected to pay a dividend of 3.69 USD.

The current dividend yield of AstraZeneca is 2.55 %.

AstraZeneca pays a dividend, distributed in the months of , , , .

AstraZeneca paid dividends every year for the past 33 years.

For the upcoming 12 months, dividends amounting to 3.69 USD are expected. This corresponds to a dividend yield of 2.08 %.

AstraZeneca is assigned to the 'Health' sector.

To receive the latest dividend of AstraZeneca from amounting to 1.6 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, AstraZeneca distributed 2.34 USD as dividends.

The dividends of AstraZeneca are distributed in USD.